Insight

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Photo from Leila Tchelebi/X

Aug 17, 2024, 07:54

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Leila Tchelebi, Associate Professor of Radiation Medicine at Zucker School of Medicine, shared a post on X, about a recent paper published in Science Direct.

“Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas”

Authors: Leila Tchelebi et al.

“Officially in print! Our QA Analysis of Alliance A021501, the 1st RCT of neoadjuvant SBRT for Pancreatic Cancer.”

Source: Leila Tchelebi/X

Adenocarcinoma Alliance A021501 Alliance for Clinical Trials in Oncology ASTRO cancer Joseph Michael Herman Leila Tchelebi Michael Chuong OncoDaily Oncology Pancreatic Cancer radiation therapy SBRT Science Direct Zucker School of Medicine

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage